Understanding the VWD Laboratory Toolbox

Jump to a test

• CBC
• PT / aPTT
• Factor VIII
• VWF Antigen
• Platelet Activity
• Multimers
• Collagen Binding
• Low-Dose RIPA
• VWF:FVIII Binding
• VWF Propeptide
• Genetics

Introduction

Diagnosing von Willebrand disease (VWD) requires much more than ordering a panel of laboratory tests. Although modern assays provide remarkable insight into VWF biology, no single test establishes or excludes the diagnosis. Each assay interrogates a different aspect of the molecule—its quantity, function, structure, interaction with platelets, ability to stabilize factor VIII, rate of clearance, or underlying genetic basis. The challenge is not simply obtaining the right tests, but understanding what biological question each test is asking and how the answer changes the diagnostic pathway.

This atlas approaches laboratory testing from the perspective of clinical reasoning rather than laboratory methodology. Instead of asking “What does this test measure?”, we ask:

• Why does this test exist?
• What biological question does it answer?
• When should it be ordered?
• How does it change diagnostic thinking?
• What uncertainty remains after the result is known?

Throughout the atlas, laboratory tests are presented as diagnostic localization tools. Each assay helps narrow the differential diagnosis by identifying where the defect lies: reduced VWF quantity, impaired VWF function, abnormal multimer distribution, defective factor VIII binding, accelerated clearance, or an underlying molecular abnormality. No test stands alone. Like pieces of a puzzle, their value comes from how they fit together.

Equally important, laboratory abnormalities do not automatically constitute disease. Advances in assay technology have made it possible to detect increasingly subtle abnormalities of VWF biology, but not every laboratory phenotype is clinically meaningful. The diagnosis of VWD requires thoughtful integration of laboratory findings with bleeding history, family history, and clinical context. The goal is not simply to identify abnormal results, but to determine whether those abnormalities explain the patient’s bleeding and justify a diagnosis of von Willebrand disease.

This atlas is organized according to the sequence in which clinicians typically approach the diagnosis. It begins with first-line screening tests, progresses to second-line localization assays, and concludes with confirmatory studies and practical guidance on choosing the next diagnostic step. Throughout, the emphasis is on helping the reader think like an experienced hematologist: using each laboratory result not as an endpoint, but as a clue that moves the diagnosis forward.

The purpose of laboratory testing is not to classify assays—it is to explain bleeding.

Complete Blood Count (CBC)

The Question This Test Answers

Has bleeding already produced hematologic consequences?

Why This Test Exists

The complete blood count (CBC) is almost always the first laboratory test obtained in a patient with suspected bleeding. Yet, unlike the specialized assays that follow, it does not evaluate von Willebrand factor itself. Instead, it asks a more fundamental question: Has bleeding already affected the blood?

Patients with VWD often have a completely normal CBC, particularly early in the course of disease or when bleeding is infrequent. Conversely, chronic or recurrent bleeding may produce iron deficiency anemia, while acute hemorrhage may result in a falling hemoglobin concentration. Thus, the CBC measures the consequences of impaired hemostasis rather than the underlying defect.

The platelet count is also informative. Although most patients with VWD have a normal platelet count, thrombocytopenia may suggest specific subtypes such as type 2B VWD or an alternative diagnosis altogether.

What the CBC Measures

The CBC provides several pieces of information relevant to patients with suspected VWD:

• Hemoglobin and hematocrit assess the presence and severity of anemia.
• Red blood cell indices may identify iron deficiency from chronic blood loss.
• Platelet count evaluates for thrombocytopenia or another hematologic disorder.
• White blood cell abnormalities generally do not reflect VWD but may indicate another medical condition.

Where It Fits in the Diagnostic Pathway

First-line screening test

The CBC is obtained in virtually every patient with suspected bleeding but does not diagnose or exclude VWD.

Typical Patterns

CBC Finding	Interpretation
Normal CBC	Does not exclude VWD, particularly mild disease
Microcytic anemia	Suggests chronic blood loss with iron deficiency
Normocytic anemia	May reflect recent bleeding or another cause of anemia
Normal platelet count	Typical for most forms of VWD
Thrombocytopenia	Consider type 2B VWD, platelet-type VWD, or another disorder

How It Changes Your Thinking

The CBC shifts the diagnostic focus from whether bleeding has occurred to whether bleeding has had measurable physiologic consequences.

A normal hemoglobin does not make VWD unlikely; many patients with mild disease bleed only intermittently. Conversely, unexplained iron deficiency—particularly in a patient with heavy menstrual bleeding or recurrent mucosal bleeding—raises suspicion that chronic blood loss has been clinically significant.

The platelet count also provides an early opportunity to localize the problem. An isolated bleeding history with a normal platelet count is compatible with many forms of VWD. Unexpected thrombocytopenia, however, broadens the differential diagnosis and should prompt consideration of disorders such as type 2B VWD, platelet-type VWD, immune thrombocytopenia, or bone marrow disease.

What the CBC Cannot Tell You

The CBC cannot:

• diagnose VWD
• distinguish among VWD subtypes
• measure VWF quantity or function
• determine bleeding risk in an individual patient

A completely normal CBC does not exclude clinically important VWD.

Clinical Pearl

The CBC tells you what bleeding has done to the patient—not why the patient is bleeding.

Common Pitfalls

• Assuming a normal hemoglobin excludes VWD.
• Attributing iron deficiency solely to dietary causes without considering chronic bleeding.
• Forgetting that pregnancy, hydration status, or acute blood loss may temporarily alter hemoglobin concentration.
• Overlooking thrombocytopenia as a clue to type 2B VWD or another diagnosis.

Diagnostic Reflection

Can a patient have clinically significant VWD with a completely normal CBC?

Yes.

Many patients with mild VWD have normal hemoglobin, normal red cell indices, and a normal platelet count between bleeding episodes. The absence of anemia does not imply the absence of a bleeding disorder. Conversely, anemia may show that bleeding has become clinically important, but it does not identify the cause.

The CBC therefore occupies a unique place in the diagnostic pathway. It is often the first test obtained, but not because it diagnoses VWD. Rather, it establishes whether bleeding has already produced measurable hematologic consequences.

Diagnostic Take-Home

The CBC tells you what bleeding has done to the patient—not why the patient is bleeding.

---

Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT)

The Question This Test Answers

Could the patient’s bleeding be explained by a coagulation disorder other than VWD—or has VWD become severe enough to reduce factor VIII?

Why This Test Exists

The PT and aPTT are among the oldest and most familiar coagulation tests, yet they are often misunderstood in the evaluation of von Willebrand disease (VWD). Neither test measures VWF directly. Instead, they provide a rapid assessment of the coagulation cascade and help determine whether another coagulation disorder may be contributing to the patient’s bleeding phenotype.

For most patients with VWD, the PT is normal because VWF has no role in the extrinsic pathway. The aPTT is also often normal, particularly in mild disease. However, because VWF serves as the carrier protein for factor VIII, severe reductions in VWF may lead to secondary factor VIII deficiency and prolongation of the aPTT.

Thus, the value of these tests lies less in diagnosing VWD than in placing VWD within the broader differential diagnosis of bleeding.

What These Tests Measure

PT evaluates the extrinsic and common coagulation pathways, primarily factors VII, X, V, II, and fibrinogen.

aPTT evaluates the intrinsic and common pathways, including factors XII, XI, IX, VIII, X, V, II, and fibrinogen.

Because factor VIII depends on VWF for stability in the circulation, severe VWF deficiency may prolong the aPTT.

Where They Fit in the Diagnostic Pathway

First-line screening tests

PT and aPTT are part of the initial evaluation of unexplained bleeding but should never be used to screen for or exclude VWD.

Typical Patterns

PT / aPTT Pattern	Interpretation
Normal PT, normal aPTT	Typical of most patients with mild VWD
Normal PT, prolonged aPTT	Consider severe VWD with secondary FVIII deficiency, type 2N VWD, hemophilia A, or another intrinsic pathway disorder
Prolonged PT	Suggests an alternative diagnosis rather than isolated VWD
Both prolonged	Consider combined coagulation disorders, liver disease, DIC, vitamin K deficiency, or anticoagulants

How They Change Your Thinking

The PT and aPTT do not answer the question:

Does this patient have VWD?

Instead, they answer a different question:

Is there evidence that another coagulation disorder—or severe factor VIII deficiency—is contributing to the bleeding phenotype?

A normal PT and aPTT should not reassure the clinician that VWD has been excluded. In fact, most patients with type 1 VWD have normal screening coagulation tests.

Conversely, a prolonged aPTT shifts the diagnostic focus toward factor VIII. The next question becomes:

Why is factor VIII low?

Possible explanations include:

• severe type 1 VWD
• type 2N VWD
• hemophilia A
• acquired hemophilia A
• acquired von Willebrand syndrome
• other intrinsic pathway factor deficiencies

The aPTT therefore acts as a signpost, directing attention toward disorders of factor VIII rather than establishing the diagnosis itself.

What These Tests Cannot Tell You

PT and aPTT cannot:

• diagnose VWD
• distinguish among VWD subtypes
• measure VWF quantity or function
• predict bleeding severity
• exclude mild VWD

A normal aPTT does not rule out VWD.

Clinical Pearl

The most common coagulation profile in VWD is a normal PT and a normal aPTT.

Common Pitfalls

• Using a normal aPTT to exclude VWD.
• Assuming every prolonged aPTT indicates hemophilia.
• Forgetting that pregnancy, stress, inflammation, and estrogen may increase factor VIII and normalize the aPTT.
• Overlooking acquired causes of prolonged aPTT in older adults with new-onset bleeding.

Diagnostic Reflection

Can a patient with severe VWD have a normal aPTT?

Yes.

The aPTT becomes prolonged only when factor VIII falls sufficiently to impair intrinsic pathway clotting. Many patients with type 1 or type 2 VWD maintain factor VIII levels high enough to produce a normal aPTT despite clinically important bleeding.

Conversely, a prolonged aPTT should not immediately be attributed to VWD. The same laboratory finding may reflect hemophilia A, acquired hemophilia, lupus anticoagulant, factor XI deficiency, or other intrinsic pathway disorders.

The aPTT therefore broadens the differential diagnosis rather than narrowing it to VWD.

Diagnostic Take-Home

PT and aPTT do not diagnose von Willebrand disease—they help determine whether VWD alone can explain the bleeding phenotype or whether another coagulation disorder should be considered.

---

Factor VIII Activity (FVIII:C)

The Question This Test Answers

Is factor VIII reduced—and if so, why?

Why This Test Exists

Factor VIII activity occupies a unique position in the evaluation of von Willebrand disease (VWD). Unlike VWF antigen or platelet-dependent VWF activity, it does not measure von Willebrand factor directly. Instead, it measures one of VWF’s most important biological functions: its ability to bind, stabilize, and protect factor VIII in the circulation.

A reduced factor VIII level may result from decreased factor VIII production, as in hemophilia A, or from accelerated factor VIII clearance because of inadequate or dysfunctional VWF. Thus, factor VIII serves as a bridge between disorders of coagulation and disorders of VWF.

For this reason, factor VIII activity is included in the initial evaluation of suspected VWD, even though it is not itself a VWF assay.

What the Test Measures

Factor VIII activity measures the functional activity of coagulation factor VIII within the intrinsic coagulation pathway.

Under normal circumstances, approximately 95% of circulating factor VIII is bound to VWF. This interaction protects factor VIII from rapid proteolytic degradation and clearance.

When VWF is markedly reduced—or unable to bind factor VIII effectively—factor VIII activity falls.

Where It Fits in the Diagnostic Pathway

First-line VWD evaluation

Factor VIII should be measured together with:

• VWF antigen
• Platelet-dependent VWF activity

Interpretation depends on all three results.

Typical Patterns

Factor VIII Pattern	Interpretation
Normal	Typical of mild type 1 VWD and many qualitative defects
Mildly reduced	Moderate quantitative deficiency or qualitative VWF defect
Disproportionately low relative to VWF	Consider type 2N VWD or hemophilia A
Markedly reduced with very low VWF	Severe type 1 or type 3 VWD
Reduced in acquired disease	Consider acquired VWS or acquired hemophilia

How It Changes Your Thinking

Factor VIII often changes the diagnostic question.

Suppose VWF antigen and platelet-dependent activity are both low.

Now ask:

What is factor VIII doing?

If factor VIII falls proportionately, the diagnosis may simply reflect reduced VWF quantity.

If factor VIII is much lower than expected, the differential diagnosis changes.

Now the possibilities include:

• Type 2N VWD
• Hemophilia A
• Acquired hemophilia A
• Acquired von Willebrand syndrome

In this way, factor VIII serves as a localization tool, directing attention toward disorders of VWF-mediated factor VIII stabilization rather than platelet adhesion.

What It Cannot Tell You

Factor VIII activity cannot:

• diagnose VWD by itself
• distinguish inherited from acquired disease
• distinguish type 2N VWD from hemophilia A
• identify the molecular abnormality

A low factor VIII level always requires interpretation alongside VWF testing.

Clinical Pearl

Factor VIII is often the clue that transforms a VWD evaluation into a diagnostic localization exercise.

Common Pitfalls

• Assuming every low factor VIII level represents hemophilia A.
• Forgetting that VWF is the principal carrier protein for factor VIII.
• Ignoring pregnancy, inflammation, or stress, all of which can substantially increase factor VIII.
• Comparing factor VIII values without considering concurrent VWF levels.

Diagnostic Reflection

Can a patient have severe factor VIII deficiency without hemophilia A?

Absolutely.

One of the most important lessons in coagulation is that factor VIII deficiency is not synonymous with hemophilia A.

Factor VIII may be reduced because:

• too little VWF is present (severe type 1 or type 3 VWD),
• VWF cannot bind factor VIII effectively (type 2N VWD),
• VWF is being removed from the circulation (acquired VWS),
• or because factor VIII itself is abnormal (hemophilia A).

The laboratory challenge is therefore not simply recognizing a low factor VIII level, but determining why it is low.

Diagnostic Take-Home

A low factor VIII level is the beginning of a diagnostic conversation—not the end of one. Always ask why factor VIII is reduced before assigning a diagnosis.

---

VWF Antigen (VWF:Ag)

The Question This Test Answers

Is there enough von Willebrand factor in the circulation?

Why This Test Exists

The first step in evaluating von Willebrand factor is determining how much is present.

VWF antigen (VWF:Ag) provides a quantitative measurement of circulating VWF protein. It answers a deceptively simple question:

Is the patient deficient in VWF?

Importantly, VWF antigen measures quantity, not quality. A patient may have very little VWF, plenty of dysfunctional VWF, or even increased amounts of abnormal VWF. Consequently, VWF antigen should never be interpreted in isolation. Its greatest value emerges when compared with platelet-dependent VWF activity.

What the Test Measures

VWF antigen quantifies the concentration of VWF protein in plasma, regardless of whether that protein functions normally.

The assay does not evaluate:

• platelet binding
• collagen binding
• factor VIII binding
• multimer distribution

It simply measures how much VWF is present.

Where It Fits in the Diagnostic Pathway

First-line VWD evaluation

VWF antigen should always be ordered together with:

• Platelet-dependent VWF activity
• Factor VIII activity

The relationship among these three assays provides the foundation for VWD diagnosis.

Typical Patterns

VWF Antigen Pattern	Interpretation
Low with proportionately low activity	Quantitative VWF deficiency (usually type 1 VWD)
Normal with disproportionately low activity	Qualitative VWF defect (type 2 VWD)
Nearly absent	Type 3 VWD
Mildly reduced	Low VWF, mild type 1 VWD, or physiologic variation
Normal or elevated	Does not exclude qualitative VWD

How It Changes Your Thinking

VWF antigen changes the diagnostic question from:

Is VWF abnormal?

to

Is the problem one of quantity or function?

If antigen and activity fall together, the diagnostic pathway moves toward quantitative deficiency.

If antigen is relatively preserved while activity falls disproportionately, attention shifts toward qualitative dysfunction.

Thus, VWF antigen is rarely interpreted by itself. Its true value lies in its relationship to platelet-dependent VWF activity.

What It Cannot Tell You

VWF antigen cannot:

• determine whether VWF functions normally
• distinguish among type 2 VWD subtypes
• identify loss of high-molecular-weight multimers
• predict bleeding severity
• establish whether a mild reduction represents disease

Normal VWF antigen does not exclude VWD.

Clinical Pearl

VWF antigen tells you how much VWF is present—it tells you nothing about how well that VWF works.

Common Pitfalls

• Diagnosing type 1 VWD from antigen alone.
• Assuming a normal antigen excludes VWD.
• Ignoring physiologic increases in VWF caused by pregnancy, stress, inflammation, or acute illness.
• Failing to interpret antigen alongside platelet-dependent VWF activity.
• Overlooking the influence of ABO blood group, particularly blood group O, which is associated with lower baseline VWF levels.

Diagnostic Reflection

Does a low VWF antigen always mean the patient has von Willebrand disease?

No.

VWF concentration exists on a continuum within the general population.

A mildly reduced antigen level may reflect:

• physiologic variation,
• blood group O,
• aging,
• transient biological fluctuation,
• or true type 1 VWD.

The diagnosis depends not simply on the antigen level, but on its relationship to bleeding history, family history, platelet-dependent activity, and the broader clinical context.

The important question is therefore not:

“Is the antigen low?”

It is:

“Does the amount of VWF present adequately explain this patient’s bleeding phenotype?”

Diagnostic Take-Home

VWF antigen measures quantity. Diagnosis begins when you compare quantity with function.

---

Platelet-Dependent VWF Activity (VWF:GPIbM, VWF:GPIbR, or VWF:RCo)

The Question This Test Answers

Does the von Willebrand factor that is present function normally?

Why This Test Exists

Knowing how much VWF is present is only half the diagnostic story.

Patients with type 1 VWD have too little VWF. Patients with type 2 VWD may have enough VWF, but much of it does not function normally. Distinguishing between these possibilities is one of the central challenges in VWD diagnosis.

The platelet-dependent VWF activity assay was developed to answer a simple but fundamental biological question:

Can circulating VWF bind platelet glycoprotein Ib (GPIb) effectively under conditions that simulate vascular injury?

Because platelet adhesion is one of the principal functions of VWF, this assay serves as the primary functional test in the evaluation of suspected VWD.

What the Test Measures

Platelet-dependent VWF activity measures the ability of circulating VWF to bind platelet glycoprotein Ib.

Historically this function was assessed with the ristocetin cofactor assay (VWF:RCo). Most laboratories now use newer assays based on recombinant or gain-of-function GPIb molecules (VWF:GPIbR or VWF:GPIbM), which provide greater precision and reproducibility while measuring the same biological function.

Although the methodologies differ, all of these assays ask essentially the same question:

Can this patient’s VWF mediate platelet adhesion?

Where It Fits in the Diagnostic Pathway

First-line VWD evaluation

This assay should always be interpreted together with:

• VWF antigen
• Factor VIII activity

Among first-line tests, it is the principal measure of VWF function.

Typical Patterns

Platelet-dependent VWF activity	VWF antigen	Interpretation
↓	↓ (proportionately)	Quantitative VWF deficiency (usually type 1)
↓↓↓	Normal or mildly ↓	Qualitative VWF defect (type 2)
Nearly absent	Nearly absent	Type 3 VWD
Normal	Normal	Clinically significant VWD less likely (but not excluded)

How It Changes Your Thinking

This assay changes the diagnostic conversation.

Before seeing the result, the question is:

Is there enough VWF?

After seeing the result, the question becomes:

Does the VWF that’s present actually work?

If activity falls in parallel with antigen, the abnormality is primarily quantitative.

If activity falls disproportionately compared with antigen, the abnormality becomes qualitative.

This distinction fundamentally changes the next diagnostic step.

Quantitative defects prompt consideration of:

• type 1 VWD
• type 3 VWD
• low VWF

Qualitative defects prompt consideration of:

• type 2A
• type 2B
• type 2M
• type 2N (after FVIII review)
• acquired VWS

Thus, platelet-dependent VWF activity serves as the principal branch point in the VWD diagnostic algorithm.

The Activity-to-Antigen Ratio

One of the most useful ways to interpret platelet-dependent VWF activity is to compare it directly with the VWF antigen.

$$\textbf{Activity-to-antigen ratio} = \frac{\text{Platelet-dependent VWF activity}}{\text{VWF antigen}}$$

Activity-to-antigen ratio=VWF antigenPlatelet-dependent VWF activity​

The ratio helps distinguish quantitative from qualitative abnormalities.

Ratio	Interpretation
Approximately proportional	Quantitative deficiency more likely
Disproportionately reduced	Qualitative VWF dysfunction more likely

Importantly, the ratio is not a diagnosis. It is a clue that directs further investigation.

What It Cannot Tell You

Platelet-dependent VWF activity cannot:

• distinguish type 2A from type 2B
• distinguish type 2M from all other qualitative defects
• identify loss of high-molecular-weight multimers
• determine whether the qualitative abnormality is inherited or acquired
• establish whether the laboratory abnormality is clinically significant

The assay identifies abnormal function.

It does not determine whether that abnormality constitutes disease.

Clinical Pearl

Never interpret platelet-dependent VWF activity without simultaneously examining the VWF antigen.

Common Pitfalls

• Diagnosing type 2 VWD from a low activity result alone.
• Ignoring the activity-to-antigen ratio.
• Assuming a low ratio automatically establishes clinically significant VWD.
• Comparing results obtained by different activity assay methodologies without recognizing their differences.
• Forgetting that stress, pregnancy, inflammation, and estrogen may substantially increase absolute VWF levels while preserving an abnormal qualitative phenotype.

Diagnostic Reflection

Does every qualitative VWF abnormality constitute von Willebrand disease?

Unlike type 1 VWD, which is defined primarily by reduced VWF quantity, type 2 VWD is defined by abnormal VWF function. A patient may therefore have a genuine qualitative VWF abnormality even when the absolute platelet-dependent VWF activity is well above 30 IU/dL.

A qualitative laboratory abnormality establishes abnormal VWF biology. It does not by itself establish clinically significant von Willebrand disease.

Whether that laboratory phenotype should be considered a disease depends on whether it is clinically meaningful. Interpretation should integrate:

• Bleeding history
• Family history
• Nonpregnant baseline VWF levels
• Activity-to-antigen ratio
• Multimer distribution
• Collagen-binding assay
• Subtype-specific testing (e.g., RIPA, VWF:FVIII binding)
• Genetic findings, when informative

The central question is therefore not:

“Is the activity assay abnormal?”

It is:

“Does this qualitative abnormality meaningfully increase bleeding risk and justify a lifelong diagnosis of von Willebrand disease?”

This distinction is particularly important during pregnancy and other physiologic states in which VWF levels rise. A patient may demonstrate an abnormal activity-to-antigen ratio despite absolute activity values within the normal range. Such findings warrant thoughtful reassessment outside pregnancy rather than immediate acceptance or dismissal of the diagnosis.

Diagnostic Take-Home

The platelet-dependent VWF activity assay identifies abnormal VWF function. The diagnosis of von Willebrand disease depends on determining whether that abnormal function is biologically real, clinically meaningful, and sufficient to explain the patient’s bleeding phenotype.

Part II. Second-Line Tests

VWF Collagen Binding (VWF:CB)

The Question This Test Answers

Is impaired VWF function due to loss of high-molecular-weight multimers or to a primary defect in collagen binding?

Why This Test Exists

Platelet-dependent VWF activity tells us whether VWF can interact with platelet glycoprotein Ib. It does not explain why that interaction is abnormal.

VWF collagen binding (VWF:CB) interrogates a different biological function of VWF: its ability to bind exposed subendothelial collagen after vascular injury.

Because high-molecular-weight (HMW) multimers bind collagen much more effectively than smaller multimers, collagen binding also serves as an indirect measure of multimer integrity.

Thus, VWF:CB is both:

• a functional assay, and
• a surrogate marker for the presence of HMW multimers.

What the Test Measures

VWF:CB measures the ability of plasma VWF to bind collagen immobilized on a solid surface.

Unlike platelet-dependent activity assays, which assess platelet binding, this assay evaluates another major function of VWF during primary hemostasis.

Its performance depends heavily on the presence of HMW multimers.

Where It Fits in the Diagnostic Pathway

Second-line localization test

Order VWF:CB when first-line testing suggests a qualitative VWF defect.

It complements:

• multimer analysis
• platelet-dependent VWF activity
• low-dose RIPA

Typical Patterns

VWF:CB Pattern	Interpretation
Reduced proportionally with antigen	Quantitative VWF deficiency
Disproportionately reduced	Loss of HMW multimers or collagen-binding defect
Normal despite reduced platelet-dependent activity	Suggests many GPIb-binding type 2M variants
Reduced with preserved multimers	Consider collagen-binding type 2M

How It Changes Your Thinking

Platelet-dependent VWF activity identifies abnormal function.

Collagen binding begins to localize which function is abnormal.

Suppose platelet-dependent activity is low.

Now ask:

Is collagen binding also impaired?

If both platelet binding and collagen binding are reduced, the most likely explanation is loss of HMW multimers, as seen in:

• type 2A VWD
• type 2B VWD
• many forms of acquired VWS

If platelet binding is impaired but collagen binding remains normal, the defect is more likely localized to platelet interaction, as in many forms of type 2M VWD.

Occasionally, collagen binding itself is selectively abnormal despite preserved multimers, reflecting variants that impair collagen interaction directly.

Thus, VWF:CB helps determine where the functional defect lies, rather than simply confirming that one exists.

What It Cannot Tell You

VWF:CB cannot:

• distinguish type 2A from type 2B
• diagnose acquired VWS
• replace multimer analysis
• establish bleeding severity
• establish disease without clinical correlation

Like every functional assay, it must be interpreted within the broader laboratory and clinical context.

Clinical Pearl

VWF collagen binding is often less a test of collagen binding than a functional surrogate for the presence of high-molecular-weight multimers.

Common Pitfalls

• Thinking VWF:CB is simply another activity assay.
• Using collagen binding instead of multimer analysis rather than alongside it.
• Assuming every reduced VWF:CB reflects a primary collagen-binding defect.
• Forgetting that assay performance depends on the collagen preparation used.
• Ignoring the VWF:CB-to-antigen relationship.

Diagnostic Reflection

Why measure collagen binding when multimer analysis already exists?

Multimer analysis tells us what the VWF molecule looks like.

Collagen binding tells us how well that molecule performs one of its major biological functions.

The two assays therefore answer different questions.

Multimer analysis provides structural information.

Collagen binding provides functional information.

Together, they greatly increase diagnostic confidence.

Diagnostic Take-Home

VWF collagen binding helps localize qualitative VWF defects by asking whether impaired function reflects loss of high-molecular-weight multimers or abnormal collagen interaction.

---

Multimer Analysis

The Question This Test Answers

What does the structure of circulating VWF look like?

Why This Test Exists

Most laboratory assays measure how much VWF is present or how well it performs a specific function.

Multimer analysis asks a different question:

What does the VWF molecule itself look like?

VWF circulates as multimers ranging from small dimers to very large, high-molecular-weight (HMW) forms. These larger multimers are the most hemostatically active because they bind platelets and collagen more efficiently under conditions of high shear stress.

Some forms of VWD selectively lose these largest multimers, whereas others preserve the normal multimer distribution despite impaired function. Multimer analysis therefore provides structural information that cannot be obtained from quantitative or functional assays alone.

Among all laboratory tests in VWD, multimer analysis comes closest to allowing the clinician to see the disease.

What the Test Measures

Multimer analysis separates circulating VWF according to molecular size using gel electrophoresis.

Rather than reporting a single number, it displays the distribution of:

• low-molecular-weight multimers
• intermediate multimers
• high-molecular-weight multimers

The result is interpreted by recognizing characteristic patterns rather than numerical thresholds.

Where It Fits in the Diagnostic Pathway

Second-line localization test

Multimer analysis is obtained when first-line testing suggests a qualitative VWF abnormality.

It helps distinguish disorders caused by loss of HMW multimers from those in which multimers remain structurally intact.

Typical Patterns

Multimer Pattern	Interpretation
Normal distribution	Type 1 VWD, many cases of type 2M, type 2N
Proportional reduction of all multimers	Type 1 VWD
Selective loss of HMW multimers	Type 2A, type 2B, many cases of acquired VWS
Nearly absent multimers	Type 3 VWD

How It Changes Your Thinking

Multimer analysis shifts the diagnostic conversation from function to structure.

If platelet-dependent VWF activity is reduced, the next question becomes:

Is the functional abnormality explained by abnormal multimer structure?

Loss of HMW multimers immediately narrows the differential diagnosis toward:

• type 2A VWD
• type 2B VWD
• many forms of acquired VWS

Conversely, a normal multimer pattern despite impaired platelet-dependent activity suggests disorders such as many forms of type 2M VWD, in which the molecule is structurally intact but functionally abnormal.

Thus, multimer analysis often transforms a broad diagnosis of “type 2 VWD” into a much smaller group of biologically related disorders.

What It Cannot Tell You

Multimer analysis cannot:

• distinguish type 2A from type 2B
• determine why HMW multimers are missing
• identify collagen-binding defects
• identify abnormal FVIII binding
• predict bleeding severity

A multimer pattern is descriptive, not diagnostic by itself.

What to Order Next

Clinical Pearl

Multimer analysis lets you see the architecture of VWF, not just measure its quantity or function.

Common Pitfalls

• Assuming every qualitative VWD subtype loses HMW multimers.
• Using multimer analysis as a screening test rather than a localization tool.
• Forgetting that acquired VWS often produces the same multimer pattern as inherited type 2A VWD.
• Interpreting multimers without first reviewing the VWF antigen and platelet-dependent activity.

Diagnostic Reflection

Why perform multimer analysis when platelet-dependent VWF activity is already abnormal?

Because functional assays tell us that VWF is abnormal.

Multimer analysis helps explain why.

Two patients may have identical reductions in platelet-dependent activity.

One has selective loss of HMW multimers.

The other has completely normal multimers.

Those two patients likely have fundamentally different diseases.

Structural information therefore provides an additional layer of diagnostic localization that cannot be obtained from quantitative or functional assays alone.

Diagnostic Take-Home

Multimer analysis transforms abnormal function into structural understanding, allowing clinicians to localize the biological defect rather than simply recognize its presence.

---

Low-Dose Ristocetin-Induced Platelet Agglutination (Low-Dose RIPA)

The Question This Test Answers

Is VWF binding platelets too readily?

Why This Test Exists

Most VWD assays ask whether VWF functions too little.

Low-dose RIPA asks the opposite question:

Is VWF functioning too much—or more precisely, is it binding platelets too easily?

Under normal conditions, VWF interacts with platelet glycoprotein Ib (GPIb) only after vascular injury and exposure to high shear stress. In type 2B VWD, however, gain-of-function variants increase the affinity of VWF for GPIb, allowing platelet binding to occur much more readily.

Low-dose RIPA was developed to expose this abnormality by using very low concentrations of ristocetin, concentrations that produce little or no platelet agglutination in normal plasma.

What the Test Measures

Low-dose RIPA measures the tendency of VWF to bind platelet GPIb under conditions of minimal ristocetin stimulation.

Normally:

• little or no platelet agglutination occurs at low ristocetin concentrations.

In type 2B VWD:

• platelet agglutination occurs at unusually low ristocetin concentrations because VWF binds platelets too readily.

The assay therefore detects enhanced platelet-VWF interaction, not simply impaired VWF function.

Where It Fits in the Diagnostic Pathway

Second-line localization test

Order low-dose RIPA when:

• platelet-dependent VWF activity is reduced,
• multimer analysis demonstrates loss of high-molecular-weight multimers,
• and type 2B VWD is being considered.

It is not a screening test.

Typical Patterns

Low-Dose RIPA Result	Interpretation
Normal	Type 1 VWD, type 2A VWD, most type 2M VWD
Increased platelet agglutination	Type 2B VWD or platelet-type VWD
Absent or reduced agglutination	Does not support type 2B VWD

How It Changes Your Thinking

After multimer analysis, the clinician may know that high-molecular-weight multimers are missing.

The next question becomes:

Why are they missing?

Two important possibilities are:

• Type 2A VWD
• Type 2B VWD

Although both may demonstrate loss of HMW multimers, their biology is fundamentally different.

In type 2A:

• multimers are absent because of defective assembly or increased susceptibility to proteolysis.

In type 2B:

• multimers are lost because abnormal VWF binds circulating platelets too readily, leading to removal of both platelets and HMW multimers from the circulation.

Low-dose RIPA distinguishes these possibilities by demonstrating abnormally increased platelet binding.

What It Cannot Tell You

Low-dose RIPA cannot:

• distinguish type 2B VWD from platelet-type VWD
• identify the responsible mutation
• predict bleeding severity
• replace genetic testing

An abnormal result narrows the differential diagnosis but does not establish the final diagnosis.

Clinical Pearl

Low-dose RIPA is not a test of VWF deficiency—it is a test of excessive VWF–platelet affinity.

Common Pitfalls

• Using low-dose RIPA as a screening test for VWD.
• Forgetting that type 2A and type 2B may have similar multimer patterns.
• Assuming an abnormal RIPA establishes type 2B VWD without excluding platelet-type VWD.
• Interpreting the assay without considering platelet count and clinical phenotype.

Diagnostic Reflection

Why isn’t low-dose RIPA performed in every patient with suspected VWD?

Because it answers a very specific question.

Most patients with suspected VWD do not have excessive platelet-VWF binding.

Low-dose RIPA becomes useful only after earlier testing has localized the defect to a qualitative abnormality, particularly one associated with loss of high-molecular-weight multimers.

Its purpose is therefore not diagnosis, but diagnostic refinement.

Diagnostic Take-Home

Low-dose RIPA identifies abnormal platelet-VWF affinity and is the key physiologic assay for distinguishing type 2B VWD from other disorders with loss of high-molecular-weight multimers.

---

VWF:FVIII Binding Assay (VWF:FVIIIB)

The Question This Test Answers

Can von Willebrand factor bind and protect factor VIII normally?

Why This Test Exists

Most laboratory tests in VWD evaluate platelet adhesion.

The VWF:FVIII binding assay evaluates a completely different function of VWF—its ability to bind, stabilize, and protect factor VIII in the circulation.

This function is essential because factor VIII has a short half-life when circulating freely. Normally, VWF acts as its carrier protein, shielding factor VIII from rapid proteolytic degradation and clearance.

Patients with type 2N VWD produce VWF in normal or near-normal amounts, and that VWF often binds platelets normally. The defect lies elsewhere: the molecule cannot bind factor VIII effectively.

The result is accelerated factor VIII clearance and a laboratory phenotype that resembles mild or moderate hemophilia A.

What the Test Measures

The assay measures the ability of patient VWF to bind factor VIII.

Unlike:

• VWF antigen (quantity),
• platelet-dependent VWF activity (platelet binding),
• or collagen binding (collagen interaction),

this assay specifically evaluates the carrier function of VWF.

Where It Fits in the Diagnostic Pathway

Second-line localization test

Order the VWF:FVIII binding assay when:

• factor VIII is disproportionately reduced relative to VWF antigen and activity,
• type 2N VWD is suspected,
• or hemophilia A remains in the differential diagnosis.

It is not part of routine first-line testing.

Typical Patterns

VWF:FVIIIB Result	Interpretation
Normal	Type 2N unlikely
Reduced	Supports type 2N VWD
Normal with isolated low FVIII	Consider hemophilia A or another cause of factor VIII deficiency

How It Changes Your Thinking

Suppose you encounter the following laboratory pattern:

Test	Result
VWF antigen	Normal
Platelet-dependent VWF activity	Normal
Factor VIII	8%

Now ask:

Why is factor VIII low?

Possibilities include:

• Hemophilia A
• Type 2N VWD
• Acquired hemophilia
• Severe acquired VWS

The VWF:FVIII binding assay answers this question by determining whether VWF can perform its carrier function normally.

If binding is defective, the diagnosis shifts toward type 2N VWD.

What It Cannot Tell You

The assay cannot:

• diagnose hemophilia A
• identify the responsible VWF mutation
• predict bleeding severity
• replace genetic testing

It establishes the presence of a functional binding defect, not its molecular cause.

Clinical Pearl

Type 2N VWD is not a disorder of platelet adhesion—it is a disorder of factor VIII protection.

Common Pitfalls

• Assuming every patient with low factor VIII has hemophilia A.
• Forgetting that normal platelet-dependent VWF activity does not exclude type 2N VWD.
• Ordering the assay when factor VIII is normal.
• Failing to integrate the result with family history and inheritance pattern.

Diagnostic Reflection

Why can type 2N VWD be mistaken for hemophilia A?

Because both disorders produce the same laboratory abnormality:

low factor VIII activity.

The difference lies in the mechanism.

In hemophilia A:

• factor VIII itself is abnormal.

In type 2N VWD:

• factor VIII is structurally normal,
• but it lacks an effective carrier protein.

The laboratory phenotype may look similar.

The biology is entirely different.

Diagnostic Take-Home

The VWF:FVIII binding assay distinguishes a defect in factor VIII from a defect in its carrier, allowing clinicians to recognize type 2N VWD when the laboratory phenotype resembles hemophilia A.

---

VWF Propeptide (VWFpp)

The Question This Test Answers

Is the low VWF level due to reduced production or accelerated clearance?

Why This Test Exists

Not all patients with low plasma VWF have the same underlying biology.

Some produce too little VWF.

Others produce a normal amount but lose it too quickly.

Those two patients may have identical VWF antigen levels but very different mechanisms of disease.

The VWF propeptide assay was developed to distinguish these possibilities.

What the Test Measures

VWF is synthesized as a large precursor protein.

Before secretion, the molecule is cleaved into:

• mature VWF
• VWF propeptide (VWFpp)

Both are released from endothelial cells in equal amounts.

After secretion, however, they behave differently.

• Mature VWF remains in the circulation for approximately 12–20 hours.
• VWF propeptide is cleared much more rapidly, with a half-life of approximately 2–3 hours.

Because both molecules are secreted together but disappear at different rates, comparing them provides insight into VWF survival.

Where It Fits in the Diagnostic Pathway

Second-line localization test

Order VWFpp when:

• VWF antigen is persistently reduced,
• accelerated VWF clearance is suspected,
• or distinguishing reduced synthesis from increased clearance will influence diagnosis or management.

Typical Patterns

VWFpp	Mature VWF	Interpretation
Both proportionately reduced	Reduced production
VWFpp relatively preserved with low mature VWF	Accelerated clearance
Elevated VWFpp:VWF ratio	Increased VWF clearance

How It Changes Your Thinking

Suppose two patients both have:

VWF antigen = 25 IU/dL

One patient has:

Normal VWFpp

↓

High VWFpp:VWF ratio

The other has:

Low VWFpp

↓

Normal ratio

Their VWF antigen is identical.

Their biology is not.

The first patient is producing VWF normally but losing it rapidly.

The second patient is simply producing less VWF.

This distinction may explain:

• poor durability of DDAVP responses
• limited pregnancy-associated rise in VWF
• recurrent postoperative bleeding despite apparently adequate initial correction

What It Cannot Tell You

VWFpp cannot:

• diagnose a specific VWD subtype
• identify the responsible mutation
• distinguish inherited from acquired clearance mechanisms
• predict bleeding severity

It localizes the mechanism of a low VWF level but does not establish its cause.

Clinical Pearl

The VWF propeptide tells you not how much VWF the patient has—but how much the patient recently made.

Common Pitfalls

• Assuming every low VWF level reflects reduced synthesis.
• Forgetting that VWFpp and mature VWF have very different half-lives.
• Ordering VWFpp as a routine first-line assay.
• Interpreting the absolute VWFpp concentration without considering the VWFpp:VWF ratio.

Diagnostic Reflection

Why does accelerated clearance matter clinically?

Two patients may have identical VWF antigen levels but respond very differently to treatment.

A patient with accelerated clearance may have an excellent initial response to DDAVP or VWF replacement, followed by a rapid decline as the newly released or infused VWF is removed from the circulation.

Recognizing accelerated clearance therefore helps explain why some patients appear to “lose” their VWF unusually quickly after treatment.

Diagnostic Take-Home

The VWF propeptide distinguishes patients who make too little VWF from those who make enough VWF but lose it too quickly.

Part III. Mechanistic & Molecular Confirmation

Genetic Testing

The Question This Test Answers

What molecular abnormality best explains the phenotype I have already localized?

Why This Test Exists

Most patients with suspected VWD can be diagnosed without genetic testing.

The diagnosis is usually established through careful integration of:

• bleeding history,
• family history,
• VWF antigen,
• platelet-dependent VWF activity,
• factor VIII,
• multimer analysis,
• and other functional assays.

Genetic testing serves a different purpose.

Rather than identifying the phenotype, it identifies the molecular explanation for the phenotype.

For this reason, genetic testing usually comes after the clinical and laboratory diagnosis has been localized.

What the Test Measures

Genetic testing evaluates the VWF gene for pathogenic variants associated with inherited VWD.

Unlike functional assays, it does not measure VWF biology directly.

Instead, it identifies DNA variants that may explain the observed laboratory phenotype.

Where It Fits in the Diagnostic Pathway

Molecular confirmation

Genetic testing is generally reserved for situations in which:

• subtype confirmation will influence management,
• the phenotype is unusual,
• family counseling is needed,
• or laboratory findings remain uncertain.

It is not a routine first-line diagnostic test.

When Genetic Testing Is Most Helpful

Clinical Situation	Value of Genetic Testing
Suspected type 2B	High
Suspected type 2N	High
Distinguishing platelet-type VWD from type 2B	High
Unusual qualitative phenotype	High
Family counseling	High
Typical type 1 VWD	Often limited
Type 3 VWD	Helpful for confirmation and counseling

How It Changes Your Thinking

Genetic testing should answer:

Does the molecular finding explain the phenotype already identified?

It should not be used to create a diagnosis in the absence of an appropriate clinical and laboratory phenotype.

For example:

A patient with:

• low platelet-dependent activity,
• loss of HMW multimers,
• enhanced low-dose RIPA,

already has a phenotype highly suggestive of type 2B VWD.

Finding a pathogenic VWF variant confirms that biological interpretation.

Conversely, identifying a variant of uncertain significance (VUS) in a patient with minimal bleeding and nonspecific laboratory abnormalities does not establish VWD.

What It Cannot Tell You

Genetic testing cannot:

• measure bleeding severity,
• predict an individual’s future bleeding,
• replace laboratory testing,
• replace clinical judgment,
• determine whether a detected variant is clinically significant.

Genotype does not always predict phenotype.

Clinical Pearl

Genetic testing explains the phenotype—it should not replace it.

Common Pitfalls

• Ordering genetics before laboratory localization.
• Diagnosing VWD solely because a VWF variant is detected.
• Assuming every VWF variant is pathogenic.
• Forgetting that many patients with type 1 VWD never require genetic confirmation.

Diagnostic Reflection

Should every patient with suspected VWD undergo genetic testing?

No.

Most patients can be diagnosed accurately through clinical evaluation and laboratory phenotyping.

Genetic testing is most valuable when it changes management or resolves diagnostic uncertainty.

The question is therefore not:

Can I find a mutation?

It is:

Will knowing the mutation improve patient care?

Diagnostic Take-Home

Phenotype comes first. Genetics explains the phenotype—it does not replace it.

---

Platelet-Type von Willebrand Disease Testing

The Question This Test Answers

Is the abnormal platelet–VWF interaction caused by the platelet rather than the von Willebrand factor?

Why This Test Exists

Type 2B VWD and platelet-type VWD are among the most difficult disorders to distinguish clinically.

Both may present with:

• mucocutaneous bleeding,
• thrombocytopenia,
• loss of high-molecular-weight multimers,
• enhanced low-dose ristocetin-induced platelet agglutination (RIPA).

The laboratory phenotype is remarkably similar.

The critical difference is where the abnormality resides.

• In type 2B VWD, the defect is in the VWF molecule.
• In platelet-type VWD, the defect is in the platelet GPIb receptor.

Because treatment decisions and genetic counseling differ, distinguishing these disorders is clinically important.

What the Test Measures

Platelet-type VWD testing determines whether excessive platelet-VWF binding results from:

• an abnormal VWF molecule, or
• an abnormal platelet receptor.

Confirmation generally requires targeted molecular testing.

Where It Fits in the Diagnostic Pathway

Molecular/mechanistic confirmation

Order testing after the phenotype has been localized to:

• enhanced platelet-VWF interaction,
• abnormal low-dose RIPA,
• and a phenotype compatible with type 2B VWD.

Typical Patterns

Finding	Type 2B VWD	Platelet-Type VWD
Low-dose RIPA	Increased	Increased
High-molecular-weight multimers	Reduced	Reduced
Platelet count	Often low	Often low
Molecular defect	VWF	GP1BA

How It Changes Your Thinking

By this point in the evaluation, the clinician already knows that:

• platelet binding is excessive,
• high-molecular-weight multimers are reduced,
• type 2B VWD is likely.

Now the remaining question becomes:

Is the excessive binding caused by abnormal VWF or abnormal platelets?

That distinction determines:

• inheritance counseling,
• molecular diagnosis,
• family screening,
• and occasionally treatment considerations.

What It Cannot Tell You

Testing cannot:

• diagnose VWD in isolation,
• replace phenotypic evaluation,
• predict bleeding severity,
• determine treatment response.

Its purpose is to localize the molecular defect, not establish the bleeding disorder itself.

Clinical Pearl

Type 2B VWD and platelet-type VWD look remarkably similar in the laboratory because one abnormal interaction can arise from defects on either side of the platelet–VWF interface.

Common Pitfalls

• Assuming enhanced RIPA automatically establishes type 2B VWD.
• Forgetting that platelet-type VWD is considerably rarer.
• Ordering platelet-type VWD testing before localizing the phenotype.
• Ignoring family history when interpreting molecular results.

Diagnostic Reflection

Why distinguish platelet-type VWD from type 2B VWD if both produce similar laboratory findings?

Because similar laboratory phenotypes do not necessarily arise from the same biology.

Type 2B VWD reflects a gain-of-function variant in VWF.

Platelet-type VWD reflects a gain-of-function variant in platelet glycoprotein Ib.

The interaction is the same.

The molecule responsible is different.

Recognizing this distinction improves diagnostic accuracy, informs family counseling, and reinforces an important principle of clinical reasoning:

The same phenotype may arise from different molecular mechanisms.

Diagnostic Take-Home

When platelet–VWF interaction is excessive, the final diagnostic step is determining whether the abnormality resides in the VWF molecule or in the platelet receptor.

Part IV. Diagnostic Reasoning

Choosing the Next Test

Turning Laboratory Results into Diagnostic Reasoning

Laboratory evaluation of von Willebrand disease (VWD) is not a checklist of assays. It is a sequence of diagnostic decisions in which each result determines the next question to ask.

Rather than ordering every available test simultaneously, experienced clinicians use the results of first-line testing to progressively localize the biological defect. Each assay narrows the differential diagnosis and determines which, if any, specialized studies are likely to be informative.

The following tables illustrate this stepwise approach.

Step 1

Is the problem quantitative or qualitative?

VWF Antigen	Platelet-Dependent Activity	Interpretation	Next Step
↓	↓ (proportionately)	Quantitative deficiency	Review bleeding phenotype; repeat testing if appropriate
Normal or mildly ↓	↓↓	Qualitative defect	Proceed to localization studies
Nearly absent	Nearly absent	Type 3 VWD likely	Confirm diagnosis; consider genetic testing

Step 2

If the defect appears qualitative, where is it localized?

Laboratory Pattern	Think	Next Test
Loss of HMW multimers	Type 2A, type 2B, acquired VWS	Low-dose RIPA
Normal multimers	Type 2M or type 2N	Review factor VIII
Reduced collagen binding with preserved multimers	Collagen-binding type 2M	Genetic testing

Step 3

Why is factor VIII low?

VWF Antigen	Platelet Activity	Factor VIII	Interpretation	Next Step
↓	↓	Mildly ↓	Type 1 or type 3 VWD	Standard evaluation
Normal	Normal	Markedly ↓	Type 2N VWD or hemophilia A	VWF:FVIII binding assay
↓	↓	Markedly ↓	Severe VWD or acquired VWS	Clinical correlation

Step 4

Are the high-molecular-weight multimers missing because of abnormal platelet binding?

Multimers	Low-Dose RIPA	Interpretation	Next Step
Reduced	Increased	Type 2B VWD or platelet-type VWD	Genetic testing
Reduced	Normal	Type 2A VWD or acquired VWS	Clinical correlation
Normal	Normal	Type 2M more likely	Genetic testing if needed

Step 5

Why is the VWF level low?

VWF Antigen	VWF Propeptide	Interpretation	Think
↓	↓ proportionately	Reduced production	Type 1 VWD
↓	Normal or relatively ↑	Accelerated clearance	Type 1C or acquired VWS

Step 6

When should genetic testing be performed?

Situation	Role of Genetic Testing
Typical type 1 VWD	Usually not required
Suspected type 2B	Helpful
Suspected type 2N	Helpful
Distinguishing type 2B from platelet-type VWD	Often essential
Unusual phenotype	Helpful
Family counseling	Helpful

---

Common Diagnostic Pathways

The Diagnostic Conversation

Every laboratory result should answer one question while raising the next.

Test	Question It Answers	New Question It Raises
CBC	Has bleeding had hematologic consequences?	Why is the patient bleeding?
PT/aPTT	Is another coagulation disorder present?	Is factor VIII involved?
Factor VIII	Is factor VIII reduced?	Why is it reduced?
VWF Antigen	Is there enough VWF?	Does it function normally?
Platelet-Dependent Activity	Does VWF function normally?	Why doesn’t it function normally?
Multimers	What does the molecule look like?	Why are multimers missing?
Collagen Binding	Which function is impaired?	Is multimer loss responsible?
Low-Dose RIPA	Is platelet binding excessive?	Is the defect in VWF or the platelet?
VWF:FVIII Binding	Can VWF protect factor VIII?	Is this type 2N?
VWF Propeptide	Is VWF disappearing too quickly?	Why is clearance accelerated?
Genetics	What mutation explains the phenotype?	Does the genotype fit the phenotype?

Diagnostic Take-Home

Every laboratory test should answer one biological question and determine the next diagnostic step.

The goal is not to order every assay available, but to use each result to progressively localize the defect until the laboratory phenotype, bleeding phenotype, and clinical context converge on a coherent diagnosis.

I think the final table—“The Diagnostic Conversation”—may be the single most distinctive feature of the atlas. It perfectly captures your educational philosophy: tests don’t exist in isolation; each one advances a conversation between the clinician and the biology. If readers remember only one page from the atlas, I suspect it will be this one.

---

Common Laboratory Patterns

Recognizing the Biology Behind the Numbers

Individual laboratory tests rarely establish the diagnosis of VWD. Instead, diagnosis emerges from recognizing recurring laboratory patterns and understanding the biology they represent.

The examples below illustrate some of the most common diagnostic phenotypes encountered in clinical practice. They are intended to guide diagnostic reasoning rather than replace clinical judgment.

Pattern 1

Proportionate Reduction in VWF

Test	Result
VWF Antigen	↓
Platelet-dependent VWF Activity	↓ (proportionately)
Activity:Antigen Ratio	Normal
Factor VIII	Normal or mildly ↓
Multimers	Proportionally reduced

Think

Quantitative VWF deficiency

Most likely diagnoses

• Type 1 VWD
• Low VWF
• Type 3 VWD (if severe)

Next steps

• Correlate with bleeding phenotype.
• Repeat testing if results are borderline.
• Consider blood group O and physiologic influences.

Pattern 2

Disproportionately Reduced Platelet-Dependent Activity

Test	Result
VWF Antigen	Normal or mildly ↓
Platelet-dependent VWF Activity	↓↓
Activity:Antigen Ratio	↓
Factor VIII	Usually normal or mildly ↓

Think

Qualitative VWF defect

Most likely diagnoses

• Type 2A
• Type 2B
• Type 2M
• Mild acquired VWS

Next steps

• Multimer analysis
• VWF collagen binding
• Low-dose RIPA
• Genetics when appropriate

Pattern 3

Markedly Reduced Factor VIII with Relatively Preserved VWF

Test	Result
VWF Antigen	Normal
Platelet-dependent VWF Activity	Normal
Factor VIII	↓↓↓

Think

Defective factor VIII stabilization

Most likely diagnoses

• Type 2N VWD
• Hemophilia A
• Acquired hemophilia A

Next steps

• VWF:FVIII binding assay
• Mixing study (when appropriate)
• Genetic testing

Pattern 4

Loss of High-Molecular-Weight Multimers

Test	Result
VWF Antigen	Variable
Platelet-dependent VWF Activity	↓↓
Multimers	Loss of HMW multimers

Think

Structural multimer abnormality

Most likely diagnoses

• Type 2A VWD
• Type 2B VWD
• Acquired VWS

Next steps

• Low-dose RIPA
• Clinical context
• Genetic testing if inherited disease suspected

Pattern 5

Enhanced Low-Dose RIPA

Test	Result
Low-dose RIPA	Increased
Multimers	Reduced HMW
Platelet count	Sometimes ↓

Think

Excessive platelet-VWF interaction

Most likely diagnoses

• Type 2B VWD
• Platelet-type VWD

Next steps

• VWF genetic testing
• GP1BA testing if VWF sequencing is negative

Pattern 6

Accelerated VWF Clearance

Test	Result
VWF Antigen	↓
VWF Propeptide	Relatively ↑
VWFpp:VWF Ratio	↑

Think

Accelerated clearance

Most likely diagnoses

• Type 1C VWD
• Acquired VWS

Next steps

• Review bleeding history.
• Consider DDAVP response.
• Consider associated disorders.

Pattern 7

Near Absence of VWF

Test	Result
VWF Antigen	Nearly absent
Platelet-dependent Activity	Nearly absent
Factor VIII	Markedly ↓
Multimers	Absent

Think

Severe quantitative deficiency

Most likely diagnosis

• Type 3 VWD

Next steps

• Genetic confirmation
• Family counseling
• Treatment planning

Diagnostic Reflection

Laboratory Patterns Are Clues—Not Diagnoses

Two patients may share an identical laboratory pattern yet have entirely different diseases.

For example:

• Loss of high-molecular-weight multimers may reflect type 2A VWD, type 2B VWD, or acquired VWS.
• Markedly reduced factor VIII may reflect type 2N VWD, hemophilia A, or acquired hemophilia.

Laboratory patterns narrow the differential diagnosis by localizing the underlying biology. They do not eliminate the need to integrate:

• bleeding phenotype,
• family history,
• age at presentation,
• associated medical conditions,
• and, when appropriate, specialized testing.

The laboratory pattern begins the diagnostic conversation. It rarely ends it.

Diagnostic Take-Home

Experienced hematologists recognize patterns before they recognize diagnoses. Laboratory patterns localize the biology; clinical judgment determines the disease.

---

Common Diagnostic Pitfalls

Avoiding the Most Frequent Errors in VWD Diagnosis

Diagnosing VWD is rarely difficult because the laboratory tests are unavailable. More often, errors arise because individual laboratory results are interpreted in isolation, physiologic changes are overlooked, or laboratory phenotypes are mistaken for disease.

The following pitfalls are among the most common encountered in clinical practice.

Pitfall 1

Using a Normal PT or aPTT to Exclude VWD

Why it happens

Clinicians often associate bleeding disorders with prolonged coagulation tests.

Why it’s misleading

Most patients with type 1 VWD—and many with type 2 VWD—have a normal PT and normal aPTT.

The aPTT becomes prolonged only when factor VIII falls sufficiently.

Better approach

Use PT and aPTT to broaden the differential diagnosis—not to screen for or exclude VWD.

Pitfall 2

Interpreting VWF Antigen Without Platelet-Dependent VWF Activity

Why it happens

VWF antigen is often viewed as “the VWD test.”

Why it’s misleading

VWF antigen measures quantity.

It tells you nothing about function.

Patients with type 2 VWD may have normal antigen levels despite clinically important qualitative abnormalities.

Better approach

Always interpret antigen together with platelet-dependent VWF activity.

Pitfall 3

Diagnosing Type 2 VWD from a Low Activity-to-Antigen Ratio Alone

Why it happens

The activity-to-antigen ratio is extremely useful and easy to calculate.

Why it’s misleading

A low ratio establishes a qualitative laboratory phenotype.

It does not establish clinically significant type 2 VWD.

Diagnosis still requires integration of:

• bleeding phenotype,
• family history,
• multimer analysis,
• collagen binding,
• subtype-specific testing,
• and, when appropriate, genetics.

Better approach

Think of the ratio as the beginning of the investigation, not the end of it.

Pitfall 4

Forgetting That VWF Is an Acute-Phase Reactant

Why it happens

Laboratory values often appear objective and stable.

Why it’s misleading

VWF increases during:

• infection
• inflammation
• surgery
• trauma
• stress
• pregnancy
• estrogen exposure

Testing during these conditions may temporarily normalize abnormal baseline values.

Better approach

Whenever possible, establish the diagnosis using samples obtained during baseline health.

Pitfall 5

Ignoring the Effect of Pregnancy

Why it happens

Normal pregnancy physiology is easily forgotten.

Why it’s misleading

Pregnancy markedly increases:

• VWF antigen
• platelet-dependent VWF activity
• factor VIII

Women with VWD may therefore have laboratory values within the normal range during pregnancy despite significantly lower baseline levels.

Better approach

Interpret pregnancy results cautiously and reassess after the postpartum physiologic changes have resolved.

Pitfall 6

Assuming Every Low VWF Level Represents Type 1 VWD

Why it happens

Low antigen naturally suggests quantitative deficiency.

Why it’s misleading

Reduced VWF may reflect:

• physiologic variation
• blood group O
• low VWF
• type 1 VWD
• accelerated clearance
• acquired VWS

Better approach

Always ask:

Why is the VWF level low?

Pitfall 7

Mistaking Acquired VWS for Inherited Disease

Why it happens

The laboratory phenotype may be identical.

Why it’s misleading

Patients with acquired VWS typically:

• bleed for the first time later in life,
• lack a family history,
• often have an associated disorder such as MGUS, Waldenström macroglobulinemia, myeloproliferative neoplasm, severe aortic stenosis, or an LVAD.

Better approach

New-onset bleeding in an older adult should always prompt consideration of acquired VWS.

Pitfall 8

Assuming Every Low Factor VIII Level Represents Hemophilia A

Why it happens

Factor VIII deficiency is strongly associated with hemophilia.

Why it’s misleading

Low factor VIII may also result from:

• type 2N VWD
• severe type 1 VWD
• type 3 VWD
• acquired VWS
• acquired hemophilia

Better approach

Always interpret factor VIII together with VWF antigen and platelet-dependent activity.

Pitfall 9

Ordering Genetic Testing Too Early

Why it happens

Modern sequencing is widely available.

Why it’s misleading

Genetic testing explains the phenotype.

It does not establish it.

Many patients with VWD can be diagnosed accurately without molecular testing.

Better approach

Localize the biological defect first.

Then use genetics to explain or confirm it.

Pitfall 10

Treating the Laboratory Instead of the Patient

Why it happens

Laboratory values are precise.

Patients are not.

Why it’s misleading

Two patients with identical VWF levels may have dramatically different bleeding phenotypes.

Conversely, patients with similar bleeding histories may have different laboratory abnormalities.

Better approach

Remember the purpose of laboratory testing:

to explain bleeding—not simply to identify abnormal biology.

---

Diagnostic Reflection

When Does an Abnormal Laboratory Phenotype Become Disease?

Modern assays increasingly identify subtle abnormalities of VWF biology.

Some patients have:

• low VWF,
• mildly abnormal activity-to-antigen ratios,
• or minor multimer abnormalities,

yet little or no clinically important bleeding.

Others bleed substantially despite relatively modest laboratory abnormalities.

The challenge is therefore not simply recognizing abnormal laboratory findings.

It is determining whether those findings meaningfully increase bleeding risk and justify a lifelong diagnosis of von Willebrand disease.

Diagnostic Take-Home

The most common diagnostic errors in VWD arise not from ordering the wrong test, but from asking the wrong question of the right test.

---

Diagnostic Reflections

1. Does Every Qualitative VWF Abnormality Constitute von Willebrand Disease?

Unlike type 1 VWD, which is defined primarily by reduced VWF quantity, type 2 VWD is defined by abnormal VWF function. A patient may therefore have a genuine qualitative VWF abnormality even when the absolute platelet-dependent VWF activity is well above 30 IU/dL.

A qualitative laboratory abnormality establishes abnormal VWF biology. It does not by itself establish clinically significant von Willebrand disease.

The diagnosis depends on whether that abnormality is reproducible, biologically coherent, and clinically meaningful.

The central question is therefore not:

“Is the assay abnormal?”

It is:

“Does this abnormality meaningfully increase bleeding risk and justify a lifelong diagnosis of von Willebrand disease?”

2. When Does Low VWF Become Disease?

VWF levels exist on a biological continuum.

Diagnostic labels do not.

Some individuals with VWF levels between 30 and 50 IU/dL have significant bleeding.

Others with lower levels do not.

No single threshold perfectly separates health from disease.

Laboratory values inform diagnosis.

They do not replace clinical judgment.

3. Can Pregnancy Mask von Willebrand Disease?

Pregnancy increases:

• VWF antigen
• platelet-dependent VWF activity
• factor VIII

These physiologic changes may temporarily normalize laboratory values in women with VWD.

An apparently normal third-trimester laboratory profile therefore does not necessarily reflect normal baseline hemostasis.

Whenever possible, definitive diagnostic evaluation should rely on measurements obtained outside pregnancy.

4. Can Two Patients Have the Same VWF Level for Completely Different Reasons?

Absolutely.

One patient may produce too little VWF.

Another may produce normal amounts but clear it rapidly.

Both have identical VWF antigen levels.

Their biology is completely different.

Understanding why the VWF level is low often matters more than knowing how low it is.

5. Is the Activity-to-Antigen Ratio a Diagnosis?

No.

The ratio is one of the most useful tools in VWD diagnosis because it distinguishes quantitative from qualitative laboratory phenotypes.

It is not a diagnosis.

A reduced ratio should prompt further localization through multimer analysis, collagen binding, subtype-specific testing, and careful clinical correlation.

The ratio changes the question.

It rarely answers it completely.

6. Why Doesn’t Every Patient Need Genetic Testing?

Genetics explains biology.

It does not replace it.

The purpose of molecular testing is not to discover whether a patient has VWD.

It is to explain a phenotype that has already been localized clinically and biologically.

In VWD, phenotype generally precedes genotype.

7. Why Doesn’t Every Patient With Low Factor VIII Have Hemophilia A?

Factor VIII deficiency is a phenotype.

Hemophilia A is one cause.

Others include:

• type 2N VWD
• severe type 1 VWD
• type 3 VWD
• acquired VWS
• acquired hemophilia

The laboratory challenge is not recognizing low factor VIII.

It is determining why it is low.

8. Can Laboratory Results Alone Diagnose von Willebrand Disease?

No.

Laboratory testing identifies biological abnormalities.

Diagnosis requires determining whether those abnormalities explain the patient’s bleeding.

A patient with striking laboratory abnormalities and no meaningful bleeding phenotype may not require the same diagnostic label—or the same treatment—as a patient with modest laboratory abnormalities and recurrent bleeding.

The purpose of laboratory testing is to explain bleeding, not simply to identify abnormal biology.

---

Final Reflection

The Laboratory Does Not Make the Diagnosis

Every assay in this atlas reveals one aspect of VWF biology.

No assay establishes the diagnosis alone.

The diagnosis of VWD emerges from the integration of:

• bleeding phenotype
• family history
• laboratory phenotype
• clinical context

Laboratory phenotypes exist on a continuum.

Diagnostic labels are binary.

The art of diagnosis lies in recognizing when the continuum has crossed the threshold into disease.

Ultimately,

the laboratory identifies abnormal biology; the clinician determines whether that biology constitutes disease.